BKYI · BIO-key International, Inc.

BIO-key International, Inc. (Nasdaq: BKYI) filed a Form 8-K on April 29, 2026, disclosing a 1-for-10 reverse stock split of its common stock. The split was approved by stockholders at a special meeting on April 20, 2026, and the board subsequently set the ratio at 1-for-10. The Certificate of Amendment was filed with the Delaware Secretary of State on April 28, 2026, and became effective at 5:00 p.m. ET on April 29, 2026. Trading on a split-adjusted basis on the Nasdaq Capital Market begins April 30, 2026, under a new CUSIP number (09060C606). Every 10 pre-split shares will convert into 1 post-split share, reducing outstanding shares from approximately 10,852,118 to approximately 1,085,212. No fractional shares will be issued; fractional interests will be rounded up to the nearest whole share. The number of authorized shares and par value remain unchanged. The company stated the split is intended to assist in regaining compliance with Nasdaq's minimum bid price requirement. This corporate action is significant for investors as it directly impacts share price and liquidity, and is a common step for companies facing potential delisting.